CLINICAL TRIALS PROFILE FOR TETRACYCLINE HYDROCHLORIDE

505(b)(2) Clinical Trials for tetracycline hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT04716426 ↗	APT™ T3X on the COVID-19 Contamination Rate	Completed	Santa Casa de Misericórdia de Porto Alegre	N/A	2021-01-28	The new coronavirus 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO), due to the alarming levels of spread, severity and inaction. Dealing with COVID-19 must be done on different fronts, such as mitigation, treatment and prevention. Therefore, strategies and therapies that can help reduce the COVID-19 rate of contamination are still important alternatives at this time of the pandemic. The Advanced Penetration Technology™ (APT™) is intellectual property owned by Patient Focused Tele-Health, LLC, a Rockwall, Texas based company. The company's focus is improving over-the-counter (OTC) topical formulations, allowing consumers better therapeutic outcomes with non-prescription medications. The Advanced Penetration Technology™ (APT™) is a patent-pending, proprietary transdermal dual carrier formulation. This formulation provides improved dermal penetration and efficacy of topical API's. Additionally, the APT™ imparts both a mechanical and biochemical effect on the microbe/fungal cell walls providing a highly effective method of destruction of microbes. These unique properties impart the broad spectrum anti-viral capability to the APT™ Tetracycline 3% formulation, breaking barriers in pharmacology and virology. The topical formulation APT™ Tetracycline 3% formulation (APT ™ T3X), is a FDA registered, Non-Prescription product. This formulation is used in an off label manner as an intranasal application for prevention of COVID-19 and other viruses. The APT™ T3X as a topical application will penetrate through and into the mucus layer and deeper. This barrier of coverage will provide a mitigation effect to decrease the viral load of exposure and infection. The efficacy of APT™ T3X is due to disrupting the lipid envelope in seconds, hence neutralizing the virus. Previous tests were performed with APT™ T3X and the results found were promising. However, these tests were performed only in vitro and clinical studies demonstrating the ability of the APT™ T3X to decrease viral exposure and contamination by COVID-19 are necessary to confirm the possible prophylactic effect, allowing the formulation to be widely distributed to the general population. Therefore, the aim of this project is to evaluate the efficacy of the APT™ T3X compared to placebo to decrease COVID-19 contamination rate in humans.
OTC	NCT04716426 ↗	APT™ T3X on the COVID-19 Contamination Rate	Completed	University of Nove de Julho	N/A	2021-01-28	The new coronavirus 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO), due to the alarming levels of spread, severity and inaction. Dealing with COVID-19 must be done on different fronts, such as mitigation, treatment and prevention. Therefore, strategies and therapies that can help reduce the COVID-19 rate of contamination are still important alternatives at this time of the pandemic. The Advanced Penetration Technology™ (APT™) is intellectual property owned by Patient Focused Tele-Health, LLC, a Rockwall, Texas based company. The company's focus is improving over-the-counter (OTC) topical formulations, allowing consumers better therapeutic outcomes with non-prescription medications. The Advanced Penetration Technology™ (APT™) is a patent-pending, proprietary transdermal dual carrier formulation. This formulation provides improved dermal penetration and efficacy of topical API's. Additionally, the APT™ imparts both a mechanical and biochemical effect on the microbe/fungal cell walls providing a highly effective method of destruction of microbes. These unique properties impart the broad spectrum anti-viral capability to the APT™ Tetracycline 3% formulation, breaking barriers in pharmacology and virology. The topical formulation APT™ Tetracycline 3% formulation (APT ™ T3X), is a FDA registered, Non-Prescription product. This formulation is used in an off label manner as an intranasal application for prevention of COVID-19 and other viruses. The APT™ T3X as a topical application will penetrate through and into the mucus layer and deeper. This barrier of coverage will provide a mitigation effect to decrease the viral load of exposure and infection. The efficacy of APT™ T3X is due to disrupting the lipid envelope in seconds, hence neutralizing the virus. Previous tests were performed with APT™ T3X and the results found were promising. However, these tests were performed only in vitro and clinical studies demonstrating the ability of the APT™ T3X to decrease viral exposure and contamination by COVID-19 are necessary to confirm the possible prophylactic effect, allowing the formulation to be widely distributed to the general population. Therefore, the aim of this project is to evaluate the efficacy of the APT™ T3X compared to placebo to decrease COVID-19 contamination rate in humans.

All Clinical Trials for tetracycline hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000120 ↗	Clinical Trial of Eye Prophylaxis in the Newborn	Completed	National Eye Institute (NEI)	Phase 3	1985-01-01	To compare the effectiveness of silver nitrate drops, erythromycin ointment, or no medication in preventing neonatal conjunctivitis caused by Chlamydia trachomatis and other eye infections. To compare side effects of the two prophylactic agents.
NCT00001683 ↗	A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer	Completed	National Cancer Institute (NCI)	Phase 1	1997-10-01	Matrix metalloproteinases (MMPs) are a class of membrane bound enzymes that are involved in the degradation of the extracellular matrix. MMP-2 and MMP-9 have been associated with the progression of cancer. It is hypothesized than an imbalance between MMPs and MMP inhibitors allows the destruction of the extracellular matrix and enhances the ability of the tumor cells to grow and metastasize. By inhibiting MMPs, it is thought that angiogenesis and metastasis can be inhibited. This is a phase I study of COL-3, an oral matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. COL-3 is a chemically modified tetracycline derivative. Patients must have clinically progressive disease documented within 1 month prior to entry to be eligible for treatment. Patients must have also failed therapy of proven efficacy for their disease and have an ECOG performance status of less or equal than 2. Patients must be willing to travel from their home to the NIH for follow-up visits. Patients with brain metastases or primary CNS malignancies are not eligible. Concurrent therapy for their cancer (i.e., radiation therapy, chemotherapy, etc.) will preclude participation. We will be defining the maximum tolerated dose, the toxicity profile, characterizing the pharmacokinetics, and evaluating the effect of COL-3 on several biological endpoints.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	National Cancer Institute (NCI)	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	M.D. Anderson Cancer Center	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.

Clinical Trial Conditions for tetracycline hydrochloride

Condition Name

Condition Name for tetracycline hydrochloride
Intervention	Trials
Helicobacter Pylori Infection	63
Acne Vulgaris	6
Dyspepsia	5
Syphilis	5

Condition MeSH

Condition MeSH for tetracycline hydrochloride
Intervention	Trials
Helicobacter Infections	47
Infections	43
Infection	35
Communicable Diseases	25

Clinical Trial Locations for tetracycline hydrochloride

Trials by Country

Trials by Country for tetracycline hydrochloride
Location	Trials
United States	161
China	44
Taiwan	32
Canada	12
Egypt	10

Trials by US State

Trials by US State for tetracycline hydrochloride
Location	Trials
California	17
Texas	10
Massachusetts	9
Ohio	8
Florida	7

Clinical Trial Progress for tetracycline hydrochloride

Clinical Trial Phase

Clinical Trial Phase for tetracycline hydrochloride
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	1
PHASE2	4

Clinical Trial Status

Clinical Trial Status for tetracycline hydrochloride
Clinical Trial Phase	Trials
Completed	112
Recruiting	46
Not yet recruiting	29

Clinical Trial Sponsors for tetracycline hydrochloride

Sponsor Name

Sponsor Name for tetracycline hydrochloride
Sponsor	Trials
National Taiwan University Hospital	16
Shandong University	12
Shanghai Jiao Tong University School of Medicine	8

Sponsor Type

Sponsor Type for tetracycline hydrochloride
Sponsor	Trials
Other	394
Industry	40
NIH	22

Tetracycline Hydrochloride Clinical Trials Update, Market Analysis, and R&D/Exclusivity Projection

Last updated: May 21, 2026

Tetracycline hydrochloride is an established, off-patent antibiotic with limited, ongoing clinical-trial activity in the modern FDA landscape. Commercial projections are primarily driven by (1) acute and chronic infection demand by country and hospital formularies, (2) generic supply stability, and (3) evolving resistance surveillance. As a result, near-term market upside is constrained by generics rather than protected product life-cycle extension.

---

Which clinical trials are currently active for tetracycline hydrochloride?

Recent clinical-trials activity for tetracycline hydrochloride is sparse compared with newer antibiotics. The largest volumes of “tetracycline” trials historically include oral tetracycline-class studies for acne/rosacea and other indications, plus formulation or bioequivalence work in many jurisdictions. In the US specifically, tetracycline hydrochloride is typically treated as an established drug where clinical innovation tends to be formulation and comparator-focused rather than new chemical entity development.

What trial types show up most often

• Bioequivalence (BA/BE) and formulation studies for oral tetracycline hydrochloride.
• Small investigator-led studies in niche infectious-disease settings.
• Observational resistance or antimicrobial stewardship studies where tetracycline is an included comparator (not always a formal trial drug).

What this means for an R&D decision

• If the goal is “new clinical evidence,” the realistic near-term path is study-specific endpoints (PK/PD, resistance phenotypes, adherence/absorption outcomes) rather than a large Phase 3 NDA-like program.
• If the goal is “market share,” the dominant lever is pricing, supply reliability, and formulary access rather than differentiation by IP.

---

What is the current FDA and regulatory status of tetracycline hydrochloride?

Featured snippet answer: Tetracycline hydrochloride is an established antibiotic with an FDA regulatory framework governed by generic drug approvals and labeling consistency rather than active exclusivity-based lifecycle incentives.

Orange Book status and what typically drives it

For established antibiotics like tetracycline hydrochloride, the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) typically shows one or more listed strengths/formulations, most with expiration dates long passed for any earlier patents. The practical regulatory bottleneck is usually product-specific compliance (manufacturing, dissolution, stability, labeling) rather than new exclusivity.

Typical regulatory pathways

• ANDA for generics using existing reference products (bioequivalence requirements).
• Occasional supplement strategies for formulation changes or labeling updates, when supported by data.

Key regulatory risk areas

• Bioavailability variability for oral tetracyclines across formulations.
• Stability and dissolution controls (especially for powder blends/tablet performance).
• Labeling constraints tied to class warnings (e.g., photosensitivity, tetracycline-class adverse events, contraindicated populations).

(Direct Orange Book listing counts and specific patent numbers for tetracycline hydrochloride vary by strength and dosage form and must be pulled from the Orange Book entry for the specific marketed strengths.)

---

How strong is the patent estate for tetracycline hydrochloride, and what patents still matter?

Featured snippet answer: Patent protection for tetracycline hydrochloride as an active moiety is effectively exhausted for most markets; any remaining enforceable rights are generally formulation-specific, method-specific, or product-manufacturing related, with narrow scope.

Where residual IP can still exist

• Process patents (API crystallization, drying, salt formation conditions).
• Specific solid-state forms or formulation recipes (though this is less common for classic tetracycline oral generics).
• New fixed-dose combinations that include tetracycline with another drug.

How to treat “strength” for business planning

• For a bidder, licensee, or investor, the economic assumption should be: no broad exclusivity moat on the base API.
• The value proposition shifts to: supply chain, regulatory readiness, manufacturing cost position, and distribution.

(Complete protection mapping requires product-specific Orange Book patent lists and active litigation checks, which depend on the specific strength and dosage form.)

---

When does tetracycline hydrochloride lose exclusivity, and what drives generic entry timing?

Featured snippet answer: There is no meaningful exclusivity window for tetracycline hydrochloride API in the aggregate; generic availability is already widespread. Timing advantages are mostly supply- and manufacturing-driven.

Main determinants of launch timing

• Availability of validated reference drug and BE bridging strategy.
• Supplier capacity for API and excipients.
• Submission approval timelines for ANDAs and supplements.
• Quality events and manufacturing interruptions.

Practical “exclusivity” in today’s market

• Even without IP barriers, wholesalers and hospital contracts can produce effective short-term scarcity advantages when supply disruptions occur.
• Those advantages are temporary and not tied to patent filings.

---

What generic entry risks exist for tetracycline hydrochloride?

Featured snippet answer: Generic entry risk is low in the sense that multiple competitors typically already exist; the real risk is supply, quality, and contract lock-in rather than legal barriers.

Where risk concentrates

• Competitive pressure on price after new entrants.
• Batch failures or OOS (out-of-spec) events causing formulary exclusion.
• Tetracycline-class sensitivity in stewardship decisions if resistance patterns worsen locally.

Common competitive outcomes

• Converging pricing toward low-cost generics in many countries.
• Differentiation often shifts to customer service, fill rates, and consistent supply.

---

How big is the tetracycline hydrochloride market, and what segments matter?

Featured snippet answer: The market is primarily an inpatient and outpatient antibiotic use case in countries where oral tetracyclines remain standard-cost options and resistance patterns allow tetracycline susceptibility.

Market segmentation that drives demand

• Geography: depends on prescribing norms and formularies.
• Indication mix: acne/rosacea legacy uses in some markets, plus infection indications where culture results support susceptibility.
• Delivery: mostly oral solid dosage forms for tetracycline-class therapy.

What drives demand volatility

• Antibiotic stewardship policies.
• Resistance trends and susceptibility data updates.
• Manufacturer supply disruptions.
• Public procurement cycles in government tenders.

---

How does tetracycline hydrochloride compare with doxycycline and minocycline on clinical and commercial positioning?

Featured snippet answer: Doxycycline and minocycline frequently take more share in modern practice due to dosing convenience and tolerability profiles, while tetracycline hydrochloride remains a low-cost option where it is clinically appropriate.

Commercial comparison logic

• If the competitor class has better adherence and comparable efficacy, it usually captures formularies.
• Tetracycline’s pricing advantage can still sustain share, especially where stewardship allows use or where formularies favor cost.

R&D comparison logic

• New differentiation for tetracycline hydrochloride requires a clear clinical benefit (not widely demonstrated for the base molecule).
• For doxycycline/minocycline, newer formulations and updated indications have had more modernization.

---

What manufacturing and formulation barriers affect tetracycline hydrochloride availability?

Featured snippet answer: The primary barriers are not IP but quality system performance, API supply continuity, and oral solid performance consistency.

Key CMC constraints

• API impurity control and polymorph/crystal behavior (where relevant).
• Consistent dissolution and bioavailability for tablets/capsules.
• Stability under temperature/humidity swings and packaging compatibility.
• GMP documentation readiness for ANDA or supplement filings.

Observed market failure modes

• Shortages from API procurement disruptions.
• Recalls tied to quality failures.
• Contract switching after repeated supply interruptions.

---

What are the realistic market projections for tetracycline hydrochloride through 2030?

Featured snippet answer: Baseline growth is likely to track modest volume changes plus inflation-adjusted pricing, with downside risk from resistance-driven stewardship restrictions and upside only from supply shocks or contract awards.

Projection framework (actionable)

Use a three-parameter model:

1. Volume trend: hospital prescribing and outpatient scripts by country.
2. Price erosion: generic competition intensity.
3. Supply continuity premium: whether capacity constraints cause temporary pricing leverage.

Base case projection

• Market value grows slowly, driven more by inflation and procurement cycle effects than by new demand creation.
• Share shifts occur across generics rather than new product category expansion.

Upside scenario

• Multi-manufacturer supply stability and contract wins drive higher share.
• If local susceptibility supports tetracycline use, formulary retention remains favorable.

Downside scenario

• Resistance surveillance results reduce tetracycline susceptibility rates in common pathogens.
• Stewardship restrictions shift prescribing to doxycycline or other antibiotic classes.

---

What competitive landscape dynamics matter most for tetracycline hydrochloride?

Key competitive axes

• Lowest landed cost and consistent supply.
• Coverage in group purchasing organization (GPO) and hospital formularies.
• Product availability across strengths (where listed strengths differ by region).

How winners typically behave

• Reduce manufacturing lead time variability.
• Maintain tight batch release specs to prevent withdrawals.
• Negotiate long-term procurement contracts to stabilize volumes.

---

Key Takeaways

• Tetracycline hydrochloride shows limited modern innovation signal because the base API is mature and broadly generic.
• Market performance is driven primarily by formulary access, price erosion, and supply continuity rather than exclusivity.
• Clinical trial activity is likely dominated by BE/formulation and small targeted studies rather than large new Phase 3 programs.
• Through 2030, projections most plausibly follow modest growth with risk tied to antimicrobial stewardship and resistance patterns, not patent-driven lifecycle events.

---

FAQs

Is tetracycline hydrochloride still used for acne or skin infections in clinical practice?

Yes in some settings where tetracycline-class therapy remains clinically appropriate and cost-effective, though doxycycline and other tetracyclines often carry higher modern prescribing share.

Are there active FDA shortages or supply disruptions for tetracycline hydrochloride?

Supply stability is the main operational concern in this category; shortage events occur by product/manufacturer and can drive temporary price and contract leverage.

Do tetracycline hydrochloride generics need bioequivalence studies?

Oral generic approvals generally require bioequivalence to a reference listed drug, with formulation-specific dissolution/performance controls.

How does tetracycline resistance risk affect market growth?

Tetracycline susceptibility declines can shift prescribing to alternative antibiotics, reducing steady demand even when the drug is low-cost.

What type of IP strategy could still create value in tetracycline hydrochloride?

Value is more likely in formulation/manufacturing improvements, combinations, or new delivery formats that produce measurable differentiation in tolerability or exposure rather than broad API-level IP.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.
3. National Library of Medicine. (n.d.). ClinicalTrials.gov. Bethesda, MD: U.S. National Institutes of Health.